Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 14Leukemia 13Leukemia, Myeloid, Acute 11Congenital Abnormalities 11Melanoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Multiple Myeloma 8Neoplasms, Plasma Cell 6Lymphoma, Follicular 6Myelodysplastic Syndromes 5Lymphoma, Non-Hodgkin 5Lymphoma, Mantle-Cell 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma 5Leukemia, Myeloid, Accelerated Phase 5Leukemia, Lymphocytic, Chronic, B-Cell 5Burkitt Lymphoma 5Unspecified Adult Solid Tumor, Protocol Specific 4Pancreatic Neoplasms 4Neuroblastoma 4Myeloproliferative Disorders 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myelomonocytic, Acute 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Head and Neck Neoplasms 4

Interventions

Sorafenib 68Bevacizumab 44Oxaliplatin 25Doxorubicin 22Gemcitabine 21Fluorouracil 21Radiosurgery 20Nivolumab 19durvalumab 18Radiofrequency Ablation 18pembrolizumab 17lenvatinib 17Cisplatin 17Capecitabine 17atezolizumab 14Leucovorin 14Hepatectomy 14Radiotherapy 12tremelimumab 10Irinotecan 10Drug Therapy 10Cyclophosphamide 10Carboplatin 10Blood Specimen Collection 10Ipilimumab 9regorafenib 8Liver Transplantation 8Everolimus 8Cryosurgery 8Chemotherapy, Adjuvant 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × Immunologic Techniques × Clear all
NCT00410956 2024-12-10

Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
22 enrolled 12 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡